Journal of Thoracic Oncology, volume 20, issue 3, pages 285-295
Improved event-free survival after complete or major pathologic response in patients with resectable NSCLC treated with neoadjuvant chemoimmunotherapy regardless of adjuvant treatment: a systematic review and individual patient data meta-analysis
Daniele Marinelli
1
,
Antonio Nuccio
2
,
Alessandro Di Federico
3
,
Francesca Ambrosi
4
,
PIETRO BERTOGLIO
5
,
Eleonora Faccioli
6
,
Roberto Ferrara
2
,
Alessandra Ferro
7
,
Raffaele Giusti
8
,
Francesco Guerrera
9
,
Marco Mammana
6
,
Alessandra Pittaro
10
,
Matteo Sepulcri
11
,
Giuseppe Viscardi
12
,
10
Department of Medical Sciences, Pathology Unit, Città della Salute e della Scienza Hospital, Turin, Italy.
|
12
Department of Pneumology and Oncology, Monaldi Hospital, AORN Ospedali dei Colli, Naples, Italy.
|
Publication type: Journal Article
Publication date: 2025-03-01
Journal:
Journal of Thoracic Oncology
scimago Q1
SJR: 7.879
CiteScore: 36.0
Impact factor: 21
ISSN: 15560864, 15561380
Abstract
Neoadjuvant chemoimmunotherapy has reshaped the treatment landscape for resectable NSCLC, yet the prognostic significance of pathologic response remains unclear. We conducted a systematic review and individual patient data (IPD) meta-analysis to evaluate the impact of achieving pCR or MPR on EFS and assessed the influence of adjuvant immunotherapy.
Are you a researcher?
Create a profile to get free access to personal recommendations for colleagues and new articles.
Profiles